- Biogen’s mixed Alzheimer’s data; Two new startups launch; and moreWelcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires blanketed much of the US Northeast this week. Hopefully things calm dow…Endpoints · 10d ago↗ source
- Midsized biotechs press White House to drop CMS pricing rulesA number of midsized biotech companies have met with White House and HHS officials in the last week, presenting their case for why two pending CMS pricing models could hinder their business and sho…Endpoints · 10d ago↗ source
- Celcuity got its cancer drug approved. Then its stock dippedThe FDA’s approval for Celcuity’s cancer drug Revtorpyk on Tuesday was widely anticipated. What Wall Street didn’t expect was that the drug could take until the end of the quarter to launch. ...